Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 22, 2017
Pharmacy Choice - Pharmaceutical News - GW-led consortium and FDA release new specifications to advance genomic data analysis - October 22, 2017

Pharmacy News Article

 10/22/17 - GW-led consortium and FDA release new specifications to advance genomic data analysis

By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA WASHINGTON () The George Washington University (GW) and the U.S. Food and Drug Administration (FDA) have published a BioCompute Object Specification Document for research and clinical trial use, which details a new framework for communication of High-throughput Sequencing (HTS) computations and data analysis, known as BioCompute Objects (BCOs). This framework will allow researchers to share and compare their work more effectively, enabling more reproducible efforts across bioinformatics as a whole. It will also facilitate workflow exchange between the FDA, pharmaceutical companies, bioinformatics platform providers and researchers as they move through the regulatory submissions process (see also George Washington University).

The work was done in collaboration with investigators from Harvard Medical School, Seven Bridges, and more.

Right now, computational researchers use a variety of bioinformatics software with different environments and parameters, which leads to variation in research protocols and difficulty reproducing results. Because there is no standard of communication, or common language used for computational biology, researchers cannot clearly communicate all the variables that impact their data analysis results, leading to the need for other researchers to expend additional time and effort to understand exactly what was done in a particular study.

"We want to make it as easy to get the exact parameters for biocomputation as it is to get a recipe for salmon," Raja Mazumder, PhD, associate professor of biochemistry and molecular medicine at the GW School of Medicine and Health Sciences. "The bioinformatics field is still evolving. With standards for BCOs, researchers will receive better information when comparing or building on existing research. It will allow all bioinformatics researchers to know the important components of the 'recipe,' so everyone is speaking the same language."

The BioCompute Object Specification Document was published on the Open Science Framework site, a free, open-source commons for scientists.

"BioCompute objects represent an important development in community-driven harmonization frameworks that meet the need for standardization as a prerequisite for a deeper understanding of community-generated nucleic acid sequence information," said Vahan Simonyan, PhD, HIVE Team Principal Investigator in FDA's Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology. "This effort has the potential to advance modern biological and medical data analysis and help improve patient health outcomes."

Major contributions were made by Gil Alterovitz of Harvard Medical School and FHIR Genomics and Dennis A. Dean of Seven Bridges Genomics.

"BCOs have the potential to profoundly transform and optimize the dissemination and communication of next-generation sequencing among potential stakeholders, including: scientific labs, clinical laboratories, and regulatory agencies," said Alterovitz, assistant professor at Harvard Medical School and the Computational Health Informatics Program, Boston Children's Hospital.

The BCO framework was created with input from over 300 key stakeholders who attended a recent workshop hosted by GW in coordination with the FDA. The attendees included medical researchers, regulatory scientists, HTS or next-generation sequencing data platform developers, pharmaceutical scientists and bioinformaticians, big data experts, and more.

"We work with numerous research and development teams across the industry and standardizing data analysis workflows is one of the biggest challenges our customers face," said Dean, senior scientist at Seven Bridges. "Having a common standard that enables greater transparency and reproducibility is absolutely key when it comes to improving the effectiveness of biomedical research and seeking regulatory approval for new therapies."

Mazumder, Simonyan, Alterovitz, and Dean also collaborated with Carol Goble and Stian Soiland-Reyes of the University of Manchester, the ELIXIR-UK node and the EU's BioExcel Centre of Excellence; Michael Crusoe of the Common Workflow Language; and Eric Donaldson from the FDA.

Keywords for this news article include: Epidemiology, George Washington University, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Oct 23: Vitamin D Primer for Pharmacy Professionals
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415